Intellia Therapeutics, Inc.
NTLA
Jodie situation report
Intellia Therapeutics, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 28 of 31 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
- At least 21 of 31 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as NRIX begins moving with the group.
Invalidation: The live read weakens if participation falls to 10 of 31 members or fewer.
Who this business touches
The relationships behind NTLA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
REGNRegeneron Pharmaceuticals, Inc.partnerMay 11, 2026 ▾
“Nex-z is the subject of a co-development and co-promotion (“Co/Co”) agreement (the “ATTR Co/Co”) with Regeneron Pharmaceuticals, Inc.”
RSReliance, Inc.partnerFeb 26, 2026 ▾
“Risks Related to Our Reliance on Third Parties Risks Related to Our Reliance on Collaboration Partners Our technological advancements and any potential for revenue may be derived in part from our collaborations, including, for example, with Regeneron Pharmace…”
Depended on by
REGNRegeneron Pharmaceuticals, Inc.partnerApr 29, 2026 ▾
“Intellia We and Intellia Therapeutics, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NTLA is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.